Business Wire

Rawbank Conducts a USD 10 Million Commercial Paper to Support the Mining Industry and Strengthen the Congolese Economy

14.1.2025 11:52:00 CET | Business Wire | Press release

Share

Rawbank, the leading bank in the Democratic Republic of Congo, announces the launch of its second issue of commercial paper for a local mining operator in the Katanga region for the sum of USD 10 million. This transaction, arranged by Rawbank's trading room, confirms the bank's role as a key player in financial innovation in the DRC, while satisfying the strategic financing needs of companies operating in major sectors of the national economy.

Following the success of its first issuance in 2022, which marked a significant step forward for the financial market in the Democratic Republic of Congo, Rawbank has affirmed its pioneering role by introducing solutions that are ever-increasingly adapted to local conditions. A major innovation in this issuance is the inclusion of a corporate guarantee - a first in the DRC - which strengthens investor security and extends the financing options available on the money market. This transaction was approved by the Central Bank of the Congo (CBC) under Instruction 50, which regulates commercial paper.

Mustafa Rawji, Chief Executive Officer of Rawbank, declared: “This transaction strengthens our leadership position in the banking sector in the DRC and underscores our commitment to support the country's economic development. By facilitating access to financing for key businesses, we are contributing to the growth and diversification of the national economy.”

Etienne Mabunda, Commercial Director of Rawbank, stated: "This second issue of commercial paper bears witness to our ability to innovate and meet the specific needs of our institutional clients. Thanks to our trading room, which complies with international standards, we were able to structure this transaction in the best possible way, thus offering our investors better yields in a competitive market environment."

The mining industry, which accounts for more than 70% of the DRC's exports, remains a vital pillar of the Congolese economy. By giving a national operator access to competitive financing, this new issuance contributes directly to boosting economic activity in the region and strengthening investor confidence while, at the same time, stimulating local savings through attractive financial products.

About Rawbank

For 23 years, with total assets of USD 5 billion, Rawbank has supported the development of the Congolese economy. The leading bank in the DRC for 12 years, Rawbank provides the most modern products and services to over 500,000 corporate, SME, and individual clients through a network of more than 100 branches across 19 provinces, a digital offering with Illicocash, internet banking, and over 250 ATMs.

Its efforts have been recognized with the African Banker Awards for Best Regional Bank in Central Africa in 2022 and 2024, a Moody’s CAA 1 rating, and ISO/IEC 20000 and ISO/IEC 27001 certifications. Rawbank’s trusted partners include IFC, BAD, TDB, BADEA, Shelter Africa, AGF, among others.

Partners who have placed their trust in RAWBANK include: AfDB, AGF, IFC, BADEA, Shelter Africa, TDB and Afrexim. For more information, visit our website:www.rawbank.com

The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250109301667/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Thales Builds Cryptographic Security for the Age of AI and Post-Quantum Computing14.9.2026 09:00:00 CEST | Press release

Thales launches Luna 8, a new hardware security module (HSM) to provide future-ready, quantum resistant security to protect critical data and applications Powered by a Thales designed cryptographic processor, it delivers unparalleled performance, enhanced protection and the flexibility to adapt to new security needs Drawing on decades of cryptographic expertise, Luna 8 combines trusted security with support for emerging technologies, including post quantum cryptography According to the 2026 Thales Data Threat Report, the threat of Harvest Now, Decrypt Later (HNDL) attacks was the top-cited risk, with 59% of organizations reporting that they are prototyping and evaluating post-quantum cryptography (PQC) algorithms to prepare for the quantum era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804748922/en/ ©Thales To help organizations turn this readiness into deployment,Thales, a global leader in advanced technologies, tod

U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations14.9.2026 09:00:00 CEST | Press release

Acceptance is based on pivotal Phase 3 data demonstrating rapid, durable and consistent skin clearance, including in high-impact sites, in a convenient once-daily pill Results from nearly 3,000 patients support potential for next-generation TYK2 inhibitor to redefine oral treatment expectations in psoriasis The Prescription Drug User Fee Act (PDUFA) target action date is in the first quarter of calendar year 2027 Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, which demonstrated rapid, durable and consistent skin clearance in Phase 3 plaque psoriasis studies.1-3 Addressing unmet needs in psoriasis treatment “Despite progress in psoriasis care, there remains a need for highly

SWISSto12 and Mitsubishi Electric Corporation Announce Strategic Partnership14.9.2026 09:00:00 CEST | Press release

The Memorandum of Understanding (MoU) and additional contract signal a new phase of collaboration on market development in the Asia Pacific (APAC) region SWISSto12 today announced a memorandum of understanding (MoU) with Mitsubishi Electric Corporation (MELCO) (TOKYO: 6503) to pursue joint opportunities on advanced payloads, radio frequency (RF) products, and market development in Japan and the APAC region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914982179/en/ Masahiko Arai, Executive Officer and Group President, Defense & Space Systems, Mitsubishi Electric, and Dr. Emile de Rijk, Chief Executive Officer, SWISSto12 Joint opportunities will leverage MELCO’s extensive satellite system expertise and integration capabilities together with SWISSto12’s proprietary 3D-printing designs and processes that form the foundation of its next-generation payloads—smaller, lighter, highly performant, yet built in materially shorter

Focused Support Launches Cavok STRIKE to Expand Link-16 Participation Across the Joint Force14.9.2026 07:00:00 CEST | Press release

Extending Link-16 interoperability without platform-level hardware integration Focused Support LLC today announced the launch of Cavok STRIKE, an integrated software capability that expands the Link-16 tactical battlespace picture by enabling additional operational platforms to participate in the Link-16 network. Modern battlefields have increasing numbers of unmanned systems, sensors, and supporting platforms operating throughout the joint battlespace. The rapid proliferation of Group 1, 2, and 3 UAS, including both expendable and recoverable systems, has created a growing need to integrate these assets into the broader tactical network. Many of these platforms provide operationally relevant information but have historically remained outside the Link-16 network due to limitations in size, weight, power, platform integration complexity, or acquisition cost. Cavok STRIKE addresses this gap by enabling platforms to participate in the Link-16 network as non-command-and-control participant

Fujirebio Expands Access to Blood-based Neurology Testing in Brazil with ANVISA Market Authorization for Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma14.9.2026 07:00:00 CEST | Press release

H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted market authorization for the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for use on the fully automated LUMIPULSE® G immunoassay platform in Brazil. “ANVISA authorization of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays marks another important step in our mission to expand access to reliable, clinically meaningful blood-based biomarkers for clinicians and patients worldwide,” said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “By making both neurological biomarker assays available to laboratories on a single, fully automated platform, we are helping support more informed clinical decision-making across a broad range of neurological conditions and throughout the diagnostic pathway.” The Brazilian ANVISA authorizations are based on the already CE marked in vitro diagnostics (IVD) approvals of these two

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye